Jan 05, 2021

Huntsman Cancer Institute Receives Press Ganey Pinnacle of Excellence Award

Huntsman Cancer Institute at the University of Utah received the Press Ganey Pinnacle of Excellence Award for their high performance in outpatient clinics. The award recognizes hospitals that have had consistent high levels over the last three years in patient experience, employee engagement, physician engagement, or clinical quality performance. HCI Hospital was in the top three highest scores for exceptional patient experience.

Dec 18, 2020

Huntsman Cancer Institute Appoints Gertz and Oliver as Cancer Center Research Program Leaders

Huntsman Cancer Institute at the University of Utah announced Jay Gertz, PhD, and Trudy G. Oliver, PhD, have accepted invitations to serve as co-leaders of Huntsman Cancer Institute Comprehensive Cancer Center research programs. Gertz will serve alongside Jared Rutter, PhD, as co-leader of the Nuclear Control of Cell Growth and Differentiation Program. Oliver will serve alongside Sheri Holmen, PhD, as co-leader of the Cell Response and Regulation Program.

Dec 17, 2020

Huntsman Cancer Institute Adds Distinguished New Members to External Advisory Board

Huntsman Cancer Institute at the University of Utah announces the appointment of four new members to its External Advisory Board: Olufunmilayo Olopade, MD, Jennifer Pietenpol, PhD, Leonidas C. Platanias, MD, PhD, and John Pounardjian, MBA. The EAB is a consultative board charged with providing insight and advice to HCI leadership to inform strategic planning decisions.

Dec 14, 2020

CDC Awards Huntsman Cancer Institute $3 Million to Increase Colorectal Cancer Screening Rates

Huntsman Cancer Institute at the University of Utah has been awarded a five-year, $3 million grant from the Centers for Disease Control and Prevention to improve Utah’s colorectal cancer screening rates. This funding will provide colorectal cancer screening and follow-up services to people between 50 and 75 years of age through partnership with health systems across Utah.

Dec 07, 2020

Huntsman Cancer Institute Treats First Non-Small Cell Lung Cancer Patient on New Phase I Clinical Trial

The first patient in the world to be enrolled on a clinical trial of a new investigational drug, AN0025, was treated at Huntsman Cancer Institute at the University of Utah earlier this year. The drug is being studied for use in patients with non-small cell lung cancer and other solid tumors who have previously been treated with immunotherapy and whose cancers later developed ways to resist immunotherapy.

Dec 03, 2020

Huntsman Cancer Institute Researchers Identify Promising Drug Combination for Melanoma

Researchers at Huntsman Cancer Institute at the University of Utah have identified a potential drug combination to treat uveal melanoma, a type of eye cancer. Lead author Amanda Truong, trainee in the McMahon Lab at HCI, explains uveal melanoma patients frequently have changes in genes called GNAQ and GNA11, which are key targets for these drugs. This study was published in the journal Clinical Cancer Research.

Nov 19, 2020

University of Utah to Speed Process of Bringing New Therapeutics to Patients

A new initiative aims to speed the process of bringing lifesaving medical discoveries made in University of Utah laboratories to new drugs and therapies for patients. The university’s Huntsman Cancer Institute, College of Pharmacy, and the Partners for Innovation, Ventures, Outreach & Technology Center have partnered to establish the University of Utah Therapeutics Accelerator Hub (U2TAH, or the Accelerator).

Nov 19, 2020

Scientists Discover Roles for a Cellular Motor in Cancer

Utah scientists have discovered new functions of a key cellular machine that regulates gene packaging and is mutated in 20% of human cancers. The study was published in print today in the journal Molecular Cell. Cairns and colleagues wanted to know how nucleosomes are moved along or removed from the DNA to unpackage and expose genes.